Glenmark Pharmaceuticals
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Glenmark Pharmaceuticals is navigating a strategic transformation towards high-margin specialty and respiratory segments, as highlighted by management's focus on innovation and disciplined capital allocation. Recent earnings calls indicate a positive outlook, with expectations of a 13-15% revenue CAGR driven by new product launches and a robust pipeline, particularly in oncology and respiratory therapies. However, the company faces margin pressures due to elevated input costs and geopolitical instability, which could challenge its profitability targets. Vista's financial outlook reflects these dynamics, projecting moderate revenue growth and EBITDA margins stabilizing around 21-22% by FY27. The Indian pharmaceutical sector's expansion, bolstered by currency depreciation and a strong export market, provides a favorable backdrop, although rising costs remain a concern. Over the next 12-24 months, key opportunities include successful commercialization of new products and potential partnerships, while watchpoints include execution risks and external economic factors that could impact growth. Overall, Glenmark's strategic pivot positions it for long-term growth, albeit with caution warranted regarding margin sustainability
Why We Like This Stock
- Management's strategic pivot towards high-margin specialty and respiratory segments is expected to drive revenue growth
- A robust pipeline, particularly in oncology and respiratory therapies, supports a projected revenue CAGR of 13-15%
- The favorable macro environment in the Indian pharmaceutical sector enhances export opportunities
Things To Watch Out For
- Margin pressures from elevated input costs and geopolitical instability could hinder profitability targets
- Execution risks associated with the ambitious innovation strategy may impact growth outcomes
- Negative foreign institutional flows could pose risks to sustained market momentum
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 11,813 | 13,322 | 16,983 | 16,570 | 18,965 |
| Profit Before Tax (Cr.) | 936 | 1,772 | 4,251 | 3,644 | 4,074 |
| PBT Margin | 7.9% | 13.3% | 2503.1% | 22.0% | 21.5% |
| Net Profit (Cr.) | -3,654 | 1,288 | 2,887 | 2,395 | 2,678 |
| Earnings Per Share | -132.0 | 45.7 | 102.4 | 84.9 | 95.0 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Choice Equity | ▲ Buy | 2,590 | 17-Jun-2026 |
| Deven Choksey | ► Add | 2,410 | 10-Jun-2026 |
| HSBC | ▲ Buy | 2,590 | 04-Aug-2026 |
| ICICI Securities | ► Hold | 2,100 | 04-Aug-2026 |
| Investec | ▲ Buy | 2,750 | 11-Jun-2026 |
| Motilal Oswal | ▲ Buy | 2,570 | 05-Aug-2026 |
Company Overview
Show Company Profile
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 TREAT trispecific T cell engager, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 2301, a NK cell engager that is in preclinical trial for solid tumors; and GRC 65327, a Cbl-b inhibitor small molecule for solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of hidradenitis suppurativa; and ISB 830-X8, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.